<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541073</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564058</org_study_id>
    <secondary_id>COL-ALIMESO</secondary_id>
    <secondary_id>INCA-RECF0441</secondary_id>
    <secondary_id>COL-2006-04</secondary_id>
    <nct_id>NCT00541073</nct_id>
  </id_info>
  <brief_title>Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving pemetrexed together with cisplatin and vitamin B12 may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II clinical trial is studying how well giving pemetrexed together with&#xD;
      cisplatin and vitamin B12 works in treating patients with mesothelioma of the chest that&#xD;
      cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Define an individually adapted (by dosage) protocol of pemetrexed disodium, cisplatin,&#xD;
           and vitamin B12 in patients with unresectable pleural mesothelioma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the relationship between pharmacokinetic and pharmacodynamic parameters&#xD;
           (hematologic and nonhematologic).&#xD;
&#xD;
        -  Analyze the inter-individual pharmacokinetic variations and the influence of the&#xD;
           covariables on the pharmacokinetics of pemetrexed disodium.&#xD;
&#xD;
        -  Analyze the impact of pharmacogenetic (MTHFR, TS, GSTpi, ERCC1, XPD) variations on the&#xD;
           toxicity of pemetrexed disodium.&#xD;
&#xD;
        -  Validate a strategy of adapting dosage.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day&#xD;
      1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients also receive vitamin B12 intramuscularly on day -7 and&#xD;
      then every 9 weeks until chemotherapy is completed.&#xD;
&#xD;
      Blood samples are collected during the first and third courses of chemotherapy. Samples are&#xD;
      analyzed by pharmacogenetic (MTHFR, TS, GSTpi, ERCC1, xPD), pharmacokinetic, and other&#xD;
      pharmacological methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Individual dosage-adapted protocol</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between pharmacokinetic and pharmacodynamic parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin B12</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed pleural mesothelioma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Clinically detected pleural effusion or ascites that cannot be controlled by drainage&#xD;
             or other procedures&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance &gt; 45 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases ≤ 3 times ULN (5 times ULN if liver metastases)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients of must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Hypersensitivity to pemetrexed disodium or any of its excipients&#xD;
&#xD;
          -  Peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Impossible to receive study therapy due to geographical, social, familial, or&#xD;
             psychological reasons&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy (21 days for injected radiotherapy)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior chemotherapy&#xD;
&#xD;
          -  Prior yellow fever vaccine&#xD;
&#xD;
          -  Inability to discontinue aspirin (&gt; 1.3 g/day) or NSAIDs for 2 days prior to, during,&#xD;
             and 2 days after day 1 of each course of study therapy&#xD;
&#xD;
          -  Concurrent participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amelie Lansiaux, MD, PhD</last_name>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>May 14, 2011</last_update_submitted>
  <last_update_submitted_qc>May 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

